Background
Methods
Study population
Imaging studies
Plasma miRNAs preparation
miRNAs array procedure
Quantitative RT-PCR (qRT-PCR) for plasma miRNAs validation
MiRNAs target prediction and pathway analysis
Statistical analysis
Results
Patient characteristics
Array phase | Validation phase | |||||
---|---|---|---|---|---|---|
S-IPF (n = 3) | AE-IPF (n = 3) | Control (n = 3) | S-IPF (n = 45) | AE-IPF (n = 12) | Control (n = 51) | |
Agea, mean ± SD | 64.3 ± 13.0 | 63.7 ± 9.7 | 64.0 ± 12.0 | 63.9 ± 11.7 | 63.6 ± 12.5 | 65.9 ± 9.7 |
Female/Male | 1/2 | 1/2 | 1/2 | 18/27 | 5/7 | 19/32 |
FVCa (% predicted), mean ± SD | 63.7 ± 17.2 | NAb
| NA | 65.7 ± 10.7 | NAb
| NA |
DLCO
a (% predicted), mean ± SD | 56.3 ± 19.1 | NAb
| NA | 51.2 ± 17.7 | NAb
| NA |
Identification of pulmonary fibrosis progress-related miRNAs in plasma
Validation of differentially expressed miRNAs between AE-IPF and S-IPF
Relative concentration to miR-16 (mean ± SD) | AUC(95% CI) | Sensitivity at 90% Specificity | |||
---|---|---|---|---|---|
AE-IPF (n = 12) | S-IPF (n = 45) | NC (n = 51) | |||
miR-25-3p | 0.0023 ± 0.0020 | 0.0002 ± 0.0001 | 0.0003 ± 0.0003 | 0.83 (0.70–0.96) | 50% |
let-7d-5p | 0.0003 ± 0.0002 | 0.0007 ± 0.0005 | 0.003 ± 0.002 | 0.75 (0.59–0.91) | 50% |
miR-25-3p + let-7d-5p | — | — | — | 0.83 (0.69–0.97) | 66.7% |
ROC analysis
Signaling pathways prediction
KEGG pathway |
p-value | let-7-5p interacted genes | miR-25-3p interacted genes |
---|---|---|---|
Glioma | 9.30E-06 | IGF1R,KRAS,CDK6,PDGFA | TP53 |
Melanoma | 6.97E-05 | IGF1R,KRAS,CDK6,PDGFA | TP53 |
Chronic myeloid leukemia | 0.0002533 | IGF1R,KRAS,CDK6 | TP53 |
Cell cycle | 0.0017125 | ESPL1,CDK6,BUB3,CDC25A | TP53,CDKN1C |
Colorectal cancer | 0.0034595 | TGFBR1,BCL2,KRAS | TP53 |
PI3K-Akt signaling pathway | 0.0043839 | THBS1,BCL2,IGF1R,KRAS,CDK6,PDGFA | TP53,BCL2L11 |
Hepatitis B | 0.0043839 | TGFBR1,BCL2,KRAS,CDK6 | TP53 |
Pancreatic cancer | 0.0049791 | IGF1R,KRAS,CDK6 | TP53 |
Bladder cancer | 0.0050961 | TGFBR1,KRAS | TP53 |
Non-small cell lung cancer | 0.0060073 | KRAS,CDK6 | TP53 |
HTLV-I infection | 0.0083159 | TGFBR1,KRAS,BUB3,ADCY9,PDGFA | TP53, AT2B |